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Assessment of somatic genomic alterations from tumors
can now be performed by sequencing circulating tumor
DNA from the cell-free component of blood. This
procedure, which identifies tumor-derived somatic
mutations from a simple blood sample, circumvents the
need for tumor tissue. A recent study highlights the
promise of circulating tumor DNA to guide therapeutic
decisions in a variety of solid tumors for both clinical
and investigative purposes, as well as providing a tool
for the early detection of cancer.sensitivity over whole-exome- and whole-genome-basedThe presence of cell-free DNA in the circulation was
first formally described by Mandel and Metais in 1948
[1]. Soon after, circulating tumor DNA (ctDNA) was
noted to be the tumor-derived fraction in the cell-free
DNA component of blood [2]. ctDNA can be detected
across many common solid tumor types in patients in
both early and late stages of cancer, with levels ranging
from less than one to greater than 100,000 mutant DNA
fragments per milliliter of plasma [3-5]. The utility of
ctDNA as a cancer biomarker hinges on the exquisite
specificity of somatic genomic alterations in patients
with cancer. Unlike other tumor biomarkers, the specifi-
city of somatic alterations is derived from the fact that
mutations are present in the genome(s) of tumor cells
but not in the genome of matched normal cells.
Many advances in this area have been possible through
recent developments in digital genomic approaches (for
example, digital PCR). These methods allow for the identi-
fication of somatic, or tumor-specific, mutations with
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unless otherwise stated.[5]. Advances in digital genomics have opened the door
for reliably evaluating very rare events in complex mix-
tures of tumor-derived and wild-type DNA. As a result,
there has been a flurry of studies that detail the biology
and clinical applicability of ctDNA [3,6,7].
One such recent study by Newman et al. [8] describes
a novel cancer profiling method for non-small cell lung
cancer (NSCLC) using deep sequencing (CAPP-Seq;
cancer personalized profiling by deep sequencing) to
quantify ctDNA. This approach allows the evaluation of
specific regions of interest contained within ctDNA, and
results in a significant cost reduction and improved
approaches. A targeted 139 gene panel, or ‘selector’, for
NSCLC was designed by analyzing whole-genome se-
quencing data for several types of somatic alterations,
including sequence mutations and translocations, and
was shown to detect >95% of cases. When applied to
plasma collected from five healthy controls and 13 pa-
tients with NSCLC, CAPP-Seq achieved a sensitivity of
85% and specificity of 96% for detection of ctDNA. A
sensitivity of 50% was achieved for patients at stage I
and 100% for those at stages II to IV, while specificity
was 96% in both groups, similar to previous evaluations
of patients with early- and late-stage disease [3].
Furthermore, until now, it has been difficult to evaluate
mutational heterogeneity within and among tumors in a
single patient because of the need for multiple tumor
biopsies. Mutational heterogeneity can also be increased
after therapy [6,7]. The less invasive nature of liquid biop-
sies, in addition to the comprehensive information they
achieve, makes this form of biopsy ideal to monitor a pa-
tient’s response to therapy and find additional mutations
that may occur over time. The Newman et al. study high-
lights the utility of liquid biopsies for this purpose when
examining two recurrently mutated genes, EGFR and
KRAS. Their CAPP-Seq method correctly identified all
mutations with allelic fractions >0.10% and yielded a spe-
cificity of 99%. Somatic mutations included two different
EGFR mutations: an activating mutation in a dominantLtd. The licensee has exclusive rights to distribute this article, in any medium, for
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in an erlotinib-resistant subclone. Of note, the mutations
were identified in both the tumor tissue and ctDNA of this
patient. Though evidence of multiple clones was found in
only a single patient, this example demonstrates the ability
of ctDNA to both address tumor heterogeneity and find
clinically relevant mutations stemming from subclonal
tumor populations.
The work presented by Newman and colleagues is yet
another step forward as it advances the practicality of
using ctDNA. However, the next phase of studies in the
field of ctDNA will be critical to define the clinical value
of this technology. What are the key next steps? First,
we need to better understand biologic sensitivity; in
other words, how much ctDNA is present in the circula-
tion at each stage of disease and across disease types.
Initial studies have begun to probe this question but, as
larger clinical studies are contemplated, it is critical to
understand both the variability in the amounts of ctDNA
present and the etiology of this variability.
Second, we need to move beyond point mutations in
order to appreciate the full spectrum of genomic alter-
ations that include aneuploidy, amplifications, deletions,
and translocations, especially because these represent
some of the most clinically useful genomic alterations in
cancer (for example, ERBB2 amplifications). This work
has begun, but only in small pilot studies, with larger
studies needed to further define these structural alter-
ations in ctDNA [9,10].
Finally, definitive clinical studies that make use of
ctDNA are crucial to advance liquid biopsy tests into
widespread practice. This will require standardization of
a platform of choice, defining the technical variability of
this platform, and then performing a properly designed
prospective study that addresses a key clinical question
involving ctDNA.
Studies like the one by Newman et al. [8] and others
[3] continue to bring ctDNA into the spotlight and
highlight the various areas in which it shows clinical
potential. The next phase of studies will further illumin-
ate the path we need to take to bring ctDNA into the
clinic as a meaningful biomarker - one that has the po-
tential to address some of the toughest clinical prob-
lems in oncology.Abbreviations
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